Paper Details

  1. Home
  2. Paper Details

Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage III myeloma. The Nagoya Myeloma Cooperative Study Group.

Author: HamajimaN, HirabayashiN, KamiyaO, KatoR, KawashimaK, KobayashiM, MizunoH, NittaM, ShimizuK, TakeyamaH

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared two chemotherapy regimens for multiple myeloma: VMCP (vincristine-melphalan-cyclophosphamide-prednisolone) and CP (cyclophosphamide-prednisolone). While no significant difference was found overall, the study found that VMCP was more effective and improved survival in patients with stage III disease. This suggests that more aggressive, multi-drug chemotherapy may be a more effective treatment for patients with more advanced multiple myeloma.
Paper Details　
Original Abstract of the Article :
A cooperative randomized clinical trial to compare the effectiveness of multi-drug combination chemotherapy (VMCP), vincristine-melphalan-cyclophosphamide-prednisolone) with CP (cyclophosphamide-prednisolone) for the treatment of multiple myeloma was performed. When the whole group of patients was e...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1349-7006.1990.tb02697.x

データ提供：米国国立医学図書館（NLM）

Multi-Drug Combination Therapy: A Powerful Approach for Treating Stage III Myeloma

Multiple myeloma, a type of cancer affecting plasma cells, can be a challenging condition to treat. This study explores the effectiveness of a multi-drug combination therapy (VMCP) compared to a standard chemotherapy regimen (CP) for treating stage III myeloma. The researchers, like expert desert navigators, conducted a randomized clinical trial to evaluate the efficacy of these two treatment approaches. Their findings suggest that VMCP may offer a more favorable outcome for patients with stage III myeloma, demonstrating the potential of multi-drug combination therapy in cancer treatment.

Multi-Drug Combination Therapy: A Potent Weapon Against Stage III Myeloma

This study, like a carefully orchestrated desert campaign, highlights the potential benefits of multi-drug combination therapy for treating stage III myeloma. The findings indicate that VMCP, a combination of vincristine, melphalan, cyclophosphamide, and prednisolone, offers a superior treatment outcome compared to standard chemotherapy. This discovery represents a significant advancement in the fight against multiple myeloma, offering a more potent weapon against this complex disease.

Multi-Drug Combination Therapy: A More Effective Approach to Cancer Treatment

This study reinforces the growing evidence supporting the effectiveness of multi-drug combination therapy in cancer treatment. By targeting different aspects of cancer cell growth and proliferation, multi-drug combinations offer a more comprehensive and effective approach to fighting this devastating disease. It's like a coordinated assault on a desert fortress, utilizing a combination of strategies to overcome the challenges of cancer.

Dr. Camel's Conclusion

This study underscores the importance of multi-drug combination therapy in treating stage III myeloma, demonstrating that this approach offers a more favorable outcome compared to standard chemotherapy. It's like a well-prepared desert caravan, utilizing a combination of resources and strategies to successfully navigate the treacherous terrain of cancer treatment.

Date :
  1. Date Completed 1991-03-06
  2. Date Revised 2019-05-10
Further Info :

Pubmed ID

2126002

DOI: Digital Object Identifier

10.1111/j.1349-7006.1990.tb02697.x

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.